Aetion Company Updates |

Company Updates

  • The A-Team was busy this week representing Aetion at conferences near and far—from Boston to Tokyo.

    On Monday, our CEO, Carolyn Magill, was at the Longwood Annual Winter Meeting to speak on the panel “Getting to drug approval” with Emil Kakkis of Ultragenyx Pharmaceutical Inc., Sandy Macrae of Sangamo Therapeutics, Inc., Roger Tung of Concert Pharmaceuticals, Inc., and Paula Soteropoulos of Akcea Therapeutics.

    On Tuesday, Carolyn joined the panel "Building a strong case for real-world evidence" at the Digital Healthcare Innovation Summit to discuss pharma-tech partnerships working to advance RWE with Rachel Sha of Sanofi, Tom Neyarapally of Sema4, and Shrujal Baxi of Flatiron Health.

    Also on Tuesday, Jeremy Rassen, our Co-founder, President, and Chief Science Officer, gave a keynote talk at HIMSS & Health 2.0 Japan 2019, titled "Using real-world evidence to answer critical questions in health care."

    Way to go, team!

  • Please join us on Tuesday, December 3, at 9:30AM EST for a webinar with eyeforpharma on how to use real-world evidence to assess drug value. Edward Lee of UCB, Pamela Bradt, MD, MPH of the Institute for Clinical and Economic Review, and Enkeleida Nikai-Fitzgerald of Janssen Europe, Middle East & Africa (EMEA) will join our CEO Carolyn Magill to discuss best practices for determining drug pricing and value using RWE, what this means for your evidence generation strategy, and how to address the risk-sharing equation to bring the right treatments to the right patients.

    Register here:

  • The Aetion team had a great week in Copenhagen for ISPOR Europe 2019. Jeremy Rassen joined the panel on the third plenary session, “Big health care data: Opportunities for research and learning,” closing out the conference with a discussion on the false dichotomies between RCTs and RWE. We’re proud of the great work our team showcased, including presentations by Sebastian Schneeweiss, Jeremy Rassen, Yin Ho, Andrew Weckstein, and Ashley Jaksa.

  • This week, we welcome a group of esteemed guests for our first annual Aetion Summit: Evidence at the Apex. We look forward to two days of great conversation and learning about real-world evidence with leaders in biopharma, academia, and medicine, including a keynote from our newest board member, Scott Gottlieb. Follow #aetionsummit for updates and live coverage.

  • This afternoon, Aetion's eclectic collective is well-represented at two industry events. Our General Counsel Lori Bennett will speak at Corporate Counsel's Women, Innovation, and Power in Law event in Washington, DC. In parallel, Kristen Coletto, Senior Director of Product, will speak at The Wharton School's 2019 Wharton Health Care Conference on Artificial Intelligence on the panel "From data to drugs: Using AI to unlock therapeutic advances" — be sure to join if you're there!

    2019 Wharton Health Care Conference on Artificial Intelligence - "A PotpourrAI" of applications

    Registration is now closed for the conference Nearby Accommodations Join the Wharton Health Care Management Alumni Association for an analysis of where machine learning and artificial intelligence are being applied. Experts in the areas of R&D, product development, customer retention, diagnosis, treatment, regulation/government oversight, NIH funding, clinical decision support, and fitness and health will be presenting.

  • On October 3, Sebastian Schneeweiss presented on using real-world data and real-world evidence to support regulatory decision-making at the Duke-Margolis Center for Health Policy event, #RWE2019. See his talk here:

    Developing Real-World Data and Evidence to Support Regulatory Decision-Making

    This conference on Developing Real-World Data and Evidence to Support Regulatory Decision-Making is funded by FDA through a cooperative agreement with the Duke-Margolis Center for Health Policy and will bring together leading experts to examine these questions, other topics addressed in the framework, as well as emerging topics in the development of real-world data and evidence.

  • We’re pleased to announce that Dr. Scott Gottlieb has joined our Board of Directors. During his tenure as FDA Commissioner, Dr. Gottlieb was a champion for the FDA’s use of real-world evidence, and his experience as a physician, regulator, and advocate will help us to continue to advance #RWE in partnership with our clients and partners.

    Learn more about this exciting news:


    NEW YORK, Sept. 17, 2019 / PRNewswire/ -- Today, Aetion, the health care technology company that delivers real-world evidence (RWE) for life sciences companies, payers, and regulatory agencies, announced that former Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb has joined its board of directors.

Work at Aetion? Share Your Experiences

  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate